BladderCa Urine Test – EI-BLA: 2-gene biomarker panel for early detection of bladder cancer from urine
The ECRG4 and ITIH5 (EI) gene promoter methylation has been identified as a novel objective biomarker panel for the diagnosis of bladder cancer (BLA) at an early stage (EI-BLA). This 2-gene panel detects bladder cancer with a specificity of 100% combined with a sensitivity of
84%. The biomarker panel is detectable in the urine sediment using standard analytical techniques (e. g. pyro-sequencing as a reliable and fast method to quantify CpG methylation). Due to the easy access to the samples the inventive method is cost-effective and convenient for the patients. Commercial Opportunities: Urinary bladder carcinoma is one of the most common cancers in human and the most expensive tumour in the US and Europe due to the need for lifelong surveillance. Cystoscopy, “the gold standard” for diagnostic evaluation of bladder cancer, is an invasive, time-consuming and cost-intensive method that is little accepted by the patients. Voided urine cytology as non-invasive method has been utilized as an additional diagnostic tool and screening test. However, the limitations of this method are found both in its comparative low sensitivity and its low objectiveness as it is dependent on the evaluation and experience of the observer. There has been great interest in identifying tumour biomarkers for a more sensitive and objective test, but the currently available, approved urine biomarkers cannot be fully recommended for clinical use. EI-BLA, the inventive 2-gene biomarker panel is more specific than any of these detection systems and thus constitutes a promising new objective approach for early bladder cancer detection. Its strong diagnostic potential has been demonstrated in a larger cohort of urine samples from bladder cancer vs. healthy controls. A further screening trial using independent (multicenter) urine samples has been initiated.
Weitere Informationen: PDF
PROvendis GmbH
Tel.: +49 (0)208/94105 10
Ansprechpartner
Dipl.-Ing. Alfred Schillert
Media Contact
Alle Nachrichten aus der Kategorie: Technologieangebote
Neueste Beiträge
Neue universelle lichtbasierte Technik zur Kontrolle der Talpolarisation
Ein internationales Forscherteam berichtet in Nature über eine neue Methode, mit der zum ersten Mal die Talpolarisation in zentrosymmetrischen Bulk-Materialien auf eine nicht materialspezifische Weise erreicht wird. Diese „universelle Technik“…
Tumorzellen hebeln das Immunsystem früh aus
Neu entdeckter Mechanismus könnte Krebs-Immuntherapien deutlich verbessern. Tumore verhindern aktiv, dass sich Immunantworten durch sogenannte zytotoxische T-Zellen bilden, die den Krebs bekämpfen könnten. Wie das genau geschieht, beschreiben jetzt erstmals…
Immunzellen in den Startlöchern: „Allzeit bereit“ ist harte Arbeit
Wenn Krankheitserreger in den Körper eindringen, muss das Immunsystem sofort reagieren und eine Infektion verhindern oder eindämmen. Doch wie halten sich unsere Abwehrzellen bereit, wenn kein Angreifer in Sicht ist?…
